Assessing the impact of a combined analysis of four common low-risk genetic variants on autism risk by Carayol, Jerome et al.
Carayol et al. Molecular Autism 2010, 1:4
http://www.molecularautism.com/content/1/1/4
Open Access RESEARCH
© 2010 Carayol et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Assessing the impact of a combined analysis of 
four common low-risk genetic variants on autism 
risk
Jerome Carayol*1, Gerard D Schellenberg2, Frederic Tores1, Jörg Hager3, Andreas Ziegler4 and Geraldine Dawson5
Abstract
Background: Autism is a complex disorder characterized by deficits involving communication, social interaction, and 
repetitive and restrictive patterns of behavior. Twin studies have shown that autism is strongly heritable, suggesting a 
strong genetic component. In other disease states with a complex etiology, such as type 2 diabetes, cancer and 
cardiovascular disease, combined analysis of multiple genetic variants in a genetic score has helped to identify 
individuals at high risk of disease. Genetic scores are designed to test for association of genetic markers with disease.
Method: The accumulation of multiple risk alleles markedly increases the risk of being affected, and compared with 
studying polymorphisms individually, it improves the identification of subgroups of individuals at greater risk. In the 
present study, we show that this approach can be applied to autism by specifically looking at a high-risk population of 
children who have siblings with autism. A two-sample study design and the generation of a genetic score using 
multiple independent genes were used to assess the risk of autism in a high-risk population.
Results: In both samples, odds ratios (ORs) increased significantly as a function of the number of risk alleles, with a 
genetic score of 8 being associated with an OR of 5.54 (95% confidence interval [CI] 2.45 to 12.49). The sensitivities and 
specificities for each genetic score were similar in both analyses, and the resultant area under the receiver operating 
characteristic curves were identical (0.59).
Conclusions: These results suggest that the accumulation of multiple risk alleles in a genetic score is a useful strategy 
for assessing the risk of autism in siblings of affected individuals, and may be better than studying single 
polymorphisms for identifying subgroups of individuals with significantly greater risk.
Background
Autism is a heterogeneous disorder characterized by
impairments in social interaction, deficits in verbal and
nonverbal communication, restricted interests and repetitive
behaviors [1]. Autism comprises the severe end of a group
of autism spectrum disorders (ASD) [2]. The prevalence of
autism is estimated at 0.2%, with males being more likely
than females to have a diagnosis of autism (ratio of approx-
imately 4:1) [3].
There is compelling evidence from twin and family stud-
ies indicating a strong genetic component in autism. The
average risk of recurrence of autism in siblings is approxi-
mately 10% [4] in families with one affected sibling, which
is much higher than the prevalence in the general popula-
tion, but much lower than would be expected for a single-
gene disease [2]. Indeed, cases of autism have only rarely
been associated with mutations in single genes or with
chromosomal duplications or other abnormalities [5-9].
Furthermore, the inheritance pattern in most cases of autism
is complex and not compatible with simple Mendelian
inheritance [10,11]. A series of common autism susceptibil-
ity genes has been identified in the literature, but taken indi-
vidually, the risk associated with these genes remains
modest. Although spontaneous mutations may help explain
isolated cases of autism, the inheritance pattern of common
variants may be at the root of autism in a large proportion of
multiplex families.
Studies using simulated data have demonstrated that the
joint analysis of such common low-risk variants has the
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potential to identify individuals at higher risk for disease,
and could be useful for complex disease prediction [12-14].
In complex disease states such as type 2 diabetes [15-19],
cancer [20,21] and cardiovascular disease [22-25], the
accumulation of multiple risk alleles markedly increases the
risk of being affected, and compared with studying single
nucleotide polymorphisms (SNPs) independently, it is bet-
ter at identifying subgroups of individuals with signifi-
cantly greater risk. Previous studies have shown
associations between several genetic variants and autism,
but many of these studies could not be replicated in differ-
ent populations.
For our study, we selected single nucleotide polymor-
phisms (SNPs) within four genes that have been previously
shown to be associated with autism. Original publications
and replication studies have shown that SLC25A12 [26-28]
and  EN2  [29,30] are associated with autism. PITX1  has
been identified through a linkage study [31] using the phys-
ical identity by descent method [32]. The same method was
used to identify ATP2B2 on chromosome 3 [33] in a region
in which different autism linkage peaks and association
with microsatellite markers have been reported [34-36]. We
sought to demonstrate that joint analysis of common low-
risk variants would have the potential to identify a subgroup
of individuals at increased risk for developing autism. To
assess the effect of combined analysis of multiple genetic
variants in autism, we conducted a primary analysis on the
first family sample using the four genes mentioned above.
The aims of this analysis were to assess the strength of the
association of the combination of these four genes with
autism in a population of affected children, and to define a
genetic scoring metric. We followed up with a second anal-
ysis to confirm our findings in an independent set of fami-
lies, including a sibling diagnosed with autism.
Methods
Family samples
The study design involved two independent family sam-
ples. The first sample came from the Autism Genetic
Resource Exchange (AGRE; http://www.agre.org) reposi-
tory (AGRE sample), and consisted of 222 families with at
least two affected offspring per family. In total, 527 affected
siblings met the diagnostic criteria for 'narrow autism'
according to the Autism Diagnostic Interview Revisited
(ADI-R). The male to female ratio was 3.5:1, which
reflected the gender distribution of autism in the general
population. In this sample, all parents and affected children
were genotyped at the four SNPs, whereas unaffected sib-
lings were not genotyped.
The second (Seattle) sample was part of the University of
Washington Family Study of Autism collection funded by
the National Institute of Child Health and Human Develop-
ment (NICHD), and consisted of 241 families with at least
two offspring, at least one of whom was affected by autism.
Additional criteria were used to categorize the 461 affected
siblings with 'narrow autism,' including the ADI-R [37], the
Autism Diagnostic Observation Schedule (ADOS-G) [38]
scores, and a clinical diagnosis by an experienced clinician
[39]. The male to female ratio was 3.7:1 and included 127
unaffected siblings as controls. The unaffected siblings
were classified based on parental report in the Family His-
tory Interview [40] and the Broader Phenotype of Autism
Symptom Scale [41].
In the Seattle sample, the IQ score as measured by the
Wechsler scale in affected siblings was (mean ± SD) 76.3 ±
26.1, and age at IQ measurement was 9.4 ± 4.1. In unaf-
fected siblings, the IQ score was 111 ± 16.3 with age at IQ
measurement being 11.6 ± 6.4, which was comparable with
the mean IQ score in parents (112.0 ± 14.0). All parents,
affected siblings and unaffected siblings were genotyped at
the four SNPs.
In the AGRE sample, single SNP analyses were con-
ducted primarily with the goal of verifying that the prese-
lected risk alleles corresponded with previous reports in the
literature. The primary goal with the Seattle sample was to
assess if the risk scores first generated in the AGRE sample
could be replicated in the Seattle sample using 'true' sibling
controls.
For both samples, exclusion criteria for children included
a diagnosis of Rett syndrome and childhood disintegrative
disorder, as defined by the Diagnostic and Statistical Man-
ual of Mental Disorders, fourth edition (DSM-IV) criteria
for other pervasive developmental disorders, presence of a
known genetic condition, history of serious head injury or
neurologic disease, or significant sensory or motor impair-
ment [39]. Ethnicity was self-reported by parents as Cauca-
sian, Asian, Hispanic or Latino, Black or African
American, Native Hawaiian or other Pacific Islander, or of
mixed ethnicities. Caucasians represented the major ethnic-
ity, with more than two-thirds of families in each sample.
Ethics approval
The study was approved by the respective institutional
review boards (IRBs), and written informed consent was
obtained from all authorized representatives. The AGRE
sample had been approved by an IRB to ensure the protec-
tion of research participants. For the Seattle sample, all
work with autism subjects was approved by the University
of Washington Human Subjects Division Review Commit-
tees.
SNP selection and genotyping
Four SNPs located in four separate genes from a pool of
genetic polymorphisms that have been associated with
autism were included in this multigene study: rs2292813 in
SLC25A12 [26,27], rs1861972 in EN2 [29,30], rs35678 in
ATP2B2 [33] and rs6872664 in PITX1 [31]. Genotyping
was performed using TaqMan allele discrimination assaysCarayol et al. Molecular Autism 2010, 1:4
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(Applied Biosystems, Foster City, CA, USA). Genotyping
was performed in 384-well plates with 5 ng genomic DNA,
0.075 μL of 20 × SNP TaqMan Assay mix, 1.5 μL of Taq-
Man Universal PCR Master Mix and 1.425 μL of dH2O in
each well. PCR was performed at 95°C for 10 minutes, fol-
lowed by 50 cycles at 92°C for 15 seconds and 60°C for 90
seconds (9700 Gene Amp PCR System; Applied Biosys-
tems). Plates were then subjected to end-point reading
(7900 Real-Time PCR System; Applied Biosystems).
Allele calls were assigned automatically, and a visual
inspection of genotype clusters was performed. Genotyping
quality was assessed by signal intensity plots and missing
genotype frequencies; any samples with poor clustering and
missing fractions ≥ 5% per SNP were re-typed. The geno-
typing success rate was found to be 97.4%. Parents' geno-
types were used to investigate Hardy-Weinberg equilibrium
(HWE) and to check for Mendelian inconsistencies. Fami-
lies with remaining inconsistencies were excluded.
Statistical analyses
Allelic frequencies were estimated for each variant in par-
ents in both population samples. All analyses excluded the
index case, defined as the oldest affected child in the fam-
ily. Odds ratios (ORs), confidence intervals (CIs) and P-
values were first calculated for all four variants individu-
ally. The sibling recurrence risk ratio attributable to the four
markers was estimated as described previously [42].
Genetic scores for combinations of SLC25A12, ATP2B2,
EN2 and PITX1 SNPs were then obtained using the allele
count model [15,16,20,24], which takes into account all
possible combinations of risk alleles by adding the number
of alleles carried by each individual under an additive
assumption expected for ATP2B2  (see Additional file 1).
Individuals with an ATP2B2  risk allele had two points
added to their genetic score if they were a homozygous car-
rier of the risk allele and zero points in all other cases,
because the association of ATP2B2 with autism follows a
recessive transmission model [33]. A subgroup analysis
was conducted for the Caucasian families only because of
the small sample sizes for all other ethnicities. Another sub-
group analysis was performed separately for males and
females using the risk score as an independent variable. For
both subgroup analyses, the 'narrow' phenotype definition
was used, and the analyses were conducted using the logis-
tic regression iterative estimating equation (IEE).
Logistic regression was used to examine the association
between the genetic score and the risk of autism, calculat-
ing the OR and CI associated with each additional risk
allele in the genetic score. Following the definition of the
reference group for single SNP OR estimates, the reference
group for the risk score was chosen based on previous data
[18,19,43] as the lower risk score. The discriminative abil-
ity of the model was evaluated, estimating sensitivity and
specificity. The sensitivity describes the proportion of
affected individuals having a genetic score above a given γ
threshold. The specificity describes the proportion of unaf-
fected individuals not having a genetic score above a given
γ threshold. The receiver operating characteristic (ROC)
curve was created by plotting sensitivity against 1 minus
specificity, and the area under the curve (AUC) was calcu-
lated using the C-statistic.
The AGRE sample did not include genotyped unaffected
siblings; specificity was not directly derived from data from
unaffected individuals. We combined the case-pseudocon-
trol approach proposed by Cordell and Clayton [44,45] with
a formula adapted from DeLong et al. [46], giving the spec-
ificity (spec) for a specific genetic score threshold γ as a
function of the OR (ORγ) and the sensitivity (sensγ) as
given in the equation below:
The OR associated with the γ threshold was calculated by
conditional logistic regression using cases and their
matched pseudocontrols. For each child with autism, a
pseudocontrol was constructed from parental untransmitted
alleles to the child with autism. Case-pseudocontrol statisti-
cal tests (developed by D. Clayton, Cambridge Institute for
Medical Research; available at: http://www-
gene.cimr.cam.ac.uk/clayton/software) were implemented
within R (statistical program language). A version that was
robust to non-independent siblings was implemented using
the DGCgenetics R library, allowing for multiple affected
offspring from the same nuclear family to be used in this
study. In the Seattle sample, the analyses were performed as
a case-control study in unaffected and affected siblings of
the proband, using a generalized estimating equation (GEE)
with a 'logit' link and the independence working correlation
matrix to adjust for familial correlation [47]. The case-
pseudocontrol design provides estimates of genetic relative
risk [44,45] rather than OR, as in the case-control design.
However, under the rare disease assumption, both estimates
are equivalent.
A supplementary analysis using a GEE to correct for sib-
ling relationship was conducted in the Seattle sample to
check for a possible association between the genetic score
and the Wechsler IQ scoring. Analyses were conducted first
on the whole case-control Seattle sample, adjusting for gen-
der and autism status, and in affected and unaffected sib-
lings adjusting for gender.
Results
None of the SNPs exhibited a departure from HWE, and
allele frequencies were similar between samples (Table 1).
All risk alleles were very common, with frequencies rang-
ing from 0.4 (ATP2B2) to 0.9 (PITX), similar to those esti-
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mated in the literature [26,27,29-31,33]. The distribution of
case subjects in both samples was similar for each genetic
score category (range 2 to 8), as was the distribution of
pseudocontrol and control subjects. Control subjects were
more often in the lower genetic score categories (≤ 4), and
the case subjects were more often in the higher genetic
score categories (> 6) (Figure 1).
A primary analysis using the AGRE sample was per-
formed to assess the association with autism of each indi-
vidual SNP used in these analyses. The ORs for
development of autism in siblings of affected children were
calculated for each SNP using data from this sample. Nom-
inally significant ORs were observed for the risk alleles for
EN2 (P = 0.02), PITX (P = 0.01) and ATP2B2 (P = 0.01)
(Table 2). Despite its reported association with autism [26-
28], the OR for SLC25A12 did not reach significance (P =
0.38). An analysis was performed in which a genetic score
was calculated (see Additional file 1), using the number of
risk alleles carried by a subject, and testing for value in pre-
dicting the risk of autism in siblings of affected children
(Table 3). A one-point increase in genetic score signifi-
cantly increased the OR for autism in siblings of affected
children (OR = 1.33; P < 0.0001). Individuals with a
genetic score of 8 had an increased risk of being affected by
autism (OR = 5.54; 95% CI 2.45 to 12.49) compared with
individuals with two risk alleles (reference group). The
same analysis was performed in the independent Seattle
sample to confirm these findings. A similar distribution of
genetic scores and ORs was observed in this analysis, with
a one-point genetic score increase giving OR = 1.32 (95%
CI 1.07 to 1.63) (Table 3). More than 50% of cases in both
analyses had a genetic score of five or six risk alleles. In the
AGRE sample, a genetic score of 5 or 6 gave ORs of 2.35
(95% CI 1.57 to 3.53) and 3.13 (95% CI 1.82 to 5.38),
respectively, and in the Seattle sample, gave ORs of 2.30
(95% CI 1.23 to 4.31) and 3.04 (95% CI 1.32 to 7.01),
respectively. Odds ratios for a one-point increase in the
genetic scores in the Caucasian subgroup from the AGRE
sample (OR = 1.39; 95% CI 1.17 to 1.66; see Additional
file 2) and the Seattle sample (OR = 1.23; 95% CI 1.02 to
1.50; see Additional file 2) were similar to the ORs (1.33
and 1.32, respectively) estimated for the complete samples
(Table 3). The ORs for gender subgroups were very similar
in both samples (see Additional file 2).
The sensitivities and specificities for each genetic score
were similar in the two samples, with overlapping CIs
(Table 4). The resultant ROC curves for the genetic scores
estimated in the two analyses (Figure 2) gave an AUC of
0.59 for both the AGRE (95% CI 0.55 to 0.64) and Seattle
(95% CI 0.53 to 0.65) samples.
In the Seattle sample, for which true controls were avail-
able, 17% of individuals with autism carried seven risk
alleles (genetic score ≥ 7) compared with only 8% of chil-
dren without autism (Figure 1). Low sensitivity of 0.17
(95% CI 0.12 to 0.22) was associated with a high specificity
of 0.93 (95% CI 0.87 to 0.98), which translated into a 2.33-
fold increased risk for autism (Table 4). In the Seattle sam-
ple, 8% of cases had a maximum genetic score of 8, com-
pared with only 2% of unaffected siblings of individuals
with autism. The specificities for an extreme genetic score
of 8 reached 0.98 (95% CI 0.96 to 1.00), but this was due to
reduction in sensitivity (0.08; 95% CI 0.04 to 0.12), leading
to a 4.44 increased risk of autism.
Based on these analyses and the distribution of the fre-
quency of genetic score, we defined a low-score group of ≤
four risk alleles, which included approximately 23% of sib-
lings, regardless of phenotype, in both samples. An inter-
mediate-score group was defined as five or six risk alleles
covering 62% and 65% of siblings and a high-score group
of ≥ seven risk alleles covered 15% and 12% of siblings in
the AGRE and Seattle samples, respectively. Using the low-
score group as the reference group, the ORs for autism in
the intermediate-risk group were 1.61 (95% CI 1.23 to
2.12) and 1.78 (95% CI 1.12 to 2.83) in the AGRE and the
Seattle samples, respectively. Similarly, ORs for the high-
risk group were 2.59 (95% CI 1.50 to 4.47) in the AGRE
sample and 3.15 (95% CI 1.25 to 7.99) in the Seattle sample
(Table 5).
We did not observe any association between the genetic
score and IQ score in the whole case-control Seattle sample
(P = 0.44), when adjusted for autism status and gender. This
was also the case in affected (P = 0.63) and unaffected (P =
0.68) siblings adjusted for gender.
Table 1: Risk allele frequency (defined as the allele associated with autism).
Gene SNP Risk allele AGRE sample Seattle sample
PITX rs6872664 C 0.89 0.90
ATP2B2 rs35678 T 0.45 0.41
SLC25A12 rs2292813 C 0.90 0.90
EN2 rs1861972 A 0.75 0.72
AGRE, Autism Genetic Resource Exchange; SNP, single nucleotide polymorphism.Carayol et al. Molecular Autism 2010, 1:4
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Figure 1 Distribution of the genetic score in pseudocontrols, controls and cases. Gray bars, distribution of (a) pseudocontrols or (b) controls; 
black bars, distribution of case subjects is indicated by black bars.
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Discussion
Complex pathologies such as autism may involve multiple
common low-risk variants that confer relatively small pre-
disposing effects. In the present study, we hypothesized that
the combined analysis of such low-risk variants would
more accurately identify a group of individuals at higher
risk of developing the disease than an analysis of indepen-
dent variants. To our knowledge, this is the first study
report of its kind in autism.
Although many variants have been described in the litera-
ture as being associated with autism, few associations have
been confirmed, possibly due to differences in methods and
sample sets used, and to the weak effect of the individual
variants. Previous studies have shown that variants in
SLC25A12 [26-28], EN2 [29,30], ATP2B2 [33] and PITX1
[31], have an association with autism. A few studies have
physiologically linked these genes to autism as well.
Expression of SLC25A12  may be involved in the
pathophysiology of autism [48] because postmortem sam-
ples of brain tissue from patients with autism have been
found to have stronger expression of SLC25A12 than nor-
mal brain samples. The EN2 gene is specifically involved in
patterning the region that gives rise to the cerebellum [49].
EN2  knockout mice exhibit neuroanatomical and behav-
ioral abnormalities that partly resemble those in patients
with autism [50]. PITX1  is a key regulator of hormonal
genes in the pituitary-hypothalamic axis. Its putative
involvement in autism is supported by evidence document-
ing abnormal levels of downstream hormones, such as adre-
nocorticotropic hormone (ACTH), beta-endorphin and
cortisol in individuals with autism [51-53]. Deregulation of
pro-opiomelanocortin and high levels of beta-endorphin in
the morning, for example, have been shown to be involved
in certain maladaptive behaviors, such as self-injurious
behaviors, which are often seen in individuals with autism
[54]. The ACTH-cortisol system, which also plays an
important role in stress-related responses, is impaired in
individuals with autism in whom lower cortisol levels and
higher ACTH levels have been reported [44,52]. Finally,
the  ATP2B2  gene codes for a major calcium pump
expressed at particularly high levels in Purkinje neurons.
Purkinje cells are involved in motor coordination, working
memory and learning. Even though the exact correlation
between Purkinje neurons and autism remains unclear,
selective loss of Purkinje cells and cerebellar atrophies are
Table 2: Results of genetic variants using the AGRE sample.
Gene SNP OR (95% CI) P
PITX rs6872664 1.58 (1.09 to 2.29) 0.01
ATP2B2 rs35678 1.74 (1.13 to 2.68) 0.01
SLC25A12 rs2292813 1.16 (0.83 to 1.64) 0.38
EN2 rs1861972 1.38 (1.06 to 1.79) 0.02
AGRE, Autism Genetic Resource Exchange; CI, confidence interval; OR, odd ratio; SNP, single nucleotide polymorphism.
Table 3: Results associated with genetic score.
Genetic score OR (95% CI)
AGRE sample Seattle sample
2a 1.00 1.00
3 1.33 (1.16 to 1.52) 1.32 (1.07 to 1.63)
4 1.77 (1.35 to 2.32) 1.74 (1.15 to 2.65)
5 2.35 (1.57 to 3.53) 2.30 (1.23 to 4.31)
6 3.13 (1.82 to 5.38) 3.04 (1.32 to 7.01)
7 4.16 (2.11 to 8.20) 4.01 (1.41 to 11.41)
8 5.54 (2.45 to 12.49) 5.30 (1.51 to 18.57)
AGRE, Autism Genetic Resource Exchange.
aReference group.Carayol et al. Molecular Autism 2010, 1:4
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the most consistently found neurological abnormalities in
people diagnosed with autism [55].
Odds ratios ranging from 1.16 to 1.74 were observed in
this study, and P values supported a nominal association for
individual variants of EN2, ATP2B2  and PITX1, but not
SLC25A12. However, because of its reported genetic asso-
ciation with autism [26,27,29] and the possible relationship
with autism of its overexpression [48], it was included in
the combined analysis. In the first stage of the combined
assessment, a primary analysis was performed to evaluate
the effect of the combination of variants as determined by
the genetic score. In the second stage, a case-control analy-
sis was performed to confirm the findings of the AGRE
sample analysis. The distribution of genetic scores and ORs
in this analysis was similar to that observed in the AGRE
sample analysis, with an OR of 1.32. The ORs for a one-
point increase in genetic score for the Caucasian subgroup
in both the AGRE and Seattle sample analyses were also
similar to those of the overall respective sample sets. We
estimated that the OR for siblings who carry > seven risk
alleles (approximately 12% of siblings), regardless of phe-
notype, was 3.15, compared with siblings who carry < four
risk alleles (approximately 23% of siblings) in the Seattle
sample, which used true sibling controls. A subgroup analy-
sis did not yield any significant differences based on gen-
der. Because of sample size, only the Caucasian subgroup
could be analyzed. The ORs for a one-point increase in
genetic score for the Caucasian subgroup in both the AGRE
and Seattle sample analyses were also similar to those of
the overall respective sample sets. We did not observe any
association between IQ and genetic score, thus, we believe
that the observed association is not an effect of the different
IQ distributions between cases and controls.
The sensitivity and specificity for each genetic score was
similar in both analyses. The resultant ROC curves for the
genetic score estimated in these analyses produced an AUC
of 0.59, significantly different (P < 0.01) from a random
prediction of the score (AUC = 0.50). These results may be
considered a first step toward the goal of using common
genetic variants at multiple loci to develop a multigene
approach to predicting the risk of autism. Indeed, these data
are in line with other multigene risk assessment models in
other complex diseases, such as type 2 diabetes, with
reported AUCs of approximately 0.6 [15,16,19,56] using 3
to 18 common genetic variants. Results from these studies
provide evidence that accumulation of multiple risk alleles
markedly increases the risk of diabetes. However, com-
pared with known nongenetic risk factors, such as body
mass index, age and family history of the disease, combina-
Table 4: Genetic score sensitivities and specificities predicting autism in siblings of affected children.
Genetic score AGRE sample Seattle sample
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
2* 1.00 0.00 1.00 0.00
3 0.99 (0.98 to 1.00) 0.02 (0.00 to 0.03) 0.99 (0.97 to 1.00) 0.01 (0.00 to 0.03)
4 0.94 (0.92 to 0.97) 0.06 (0.03 to 0.09) 0.95 (0.92 to 0.98) 0.04 (0.00 to 0.07)
5 0.81 (0.76 to 0.86) 0.26 (0.21 to 0.31) 0.81 (0.75 to 0.87) 0.26 (0.18 to 0.35)
6 0.50 (0.44 to 0.56) 0.67 (0.61 to 0.73) 0.50 (0.43 to 0.57) 0.65 (0.55 to 0.74)
7 0.19 (0.14 to 0.25) 0.91 (0.87 to 0.96) 0.17 (0.12 to 0.22) 0.93 (0.87 to 0.98)
8 0.09 (0.05 to 0.12) 0.98 (0.96 to 1.00) 0.08 (0.04 to 0.12) 0.98 (0.96 to 1.00)
AGRE, Autism Genetic Resource Exchange; CI, confidence interval.
aReference group.
Figure 2 Area under the receiver operating characteristic (ROC) 
curve (AUC) for the AGRE and Seattle samples. ROC curve for the 
genetic score in the Autism Genetic Resource Exchange (AGRE) sam-
ple (gray line; AUC = 0.59, 95% CI 0.55 to 0.64) and the Seattle sample 
(black line; AUC = 0.59, 95% CI 0.53 to 0.65). Dashed line is reference 
value (AUC = 0.5).
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tion of risk alleles provides only a relatively small increase
in risk prediction [19,56,57]. In the case of autism, no early
predictors exist to compare with genetic score. Neverthe-
less, there is significant interest in the early identification of
infants at higher risk for autism because studies have shown
that early intervention leads to significantly improved long-
term outcome for the whole family [58,59].
The AUC is not a clinically relevant way of summarizing
predictive performances. Furthermore, the AUC is a poor
metric for evaluating markers for disease diagnoses, screen-
ing or prognosis [60]. Using a threshold of six risk alleles
allows identification of 18% of cases (19% and 17% in the
AGRE and Seattle samples, respectively) while reducing
the likelihood of false-positive results (around 8%). Impor-
tantly, these sensitivity and specificity values translate into
a > 2-fold increased risk for autism. In such a disorder,
defined entirely on the basis of child behavior, this can be
considered an important first step toward improved risk
prediction.
Several studies support a strong genetic contribution to
the etiology of autism, including twin studies that estimated
a heritability of > 90% [61,62] and a family study that indi-
cated a sibling recurrence risk ratio of 22 [63], which indi-
cate that there is much potential for genetic prediction in
autism. In the current study, the four SNPs used in the score
are associated with a sibling recurrence risk ratio of 1.8.
These results demonstrate that up to 10% of the variation in
risk could be explained by these four genes.
Several strategies exist to identify relevant variants to be
combined in a genetic score. These range from conservative
approaches using only well-established factors
[16,56,64,65] to more liberal approaches, which include
polymorphisms from candidate genes or from regions that
have already been associated with the disease or that dis-
play functional relevance [20,22,66]. We selected a subset
of four variants from four candidate genes already associ-
ated with autism. An additional strategy would have been to
include genes identified in a genome-wide association
study [43]. The approach described here could be applied to
other established variants and be part of future studies.
Only one recent paper reported genome-wide scan results,
which identified a common genetic variant reaching
genome-wide significance located on 5p14.1 in the inter-
genic region between the CDH10 and CDH9 genes [67].
The reported ORs for the associated variant were similar to
those of the variants in this study. However, it would be
interesting to add this variant into the risk score. In our
study, we chose the risk allele count as the most commonly
used method of constructing genetic scores from low-effect
genetic variants [15,16,20,24]. We used a recessive model
to calculate the effect of ATP2B2, thereby strengthening our
genetic score. Weighted scores have been proposed to
increase discriminative power, but models that introduce
information from variants with similar, small or moderate
effect size only slightly increased the AUC [19,55].
One limitation of our study was that we assumed an indi-
vidual effect for each gene. Gene by gene and/or gene by
environment interaction should be tested and could be
introduced into the genetic score for a more accurate assess-
ment of risk associated with a given genetic score. Another
limitation was that the polymorphisms used are probably
not causal variants but rather markers in linkage disequilib-
rium. Causal variants may have different allele distributions
in siblings with and without autism, and could have a stron-
ger effect on disease risk. This is not yet clearly established
and needs to be clarified [68].
Surprisingly, for three of the four loci investigated in this
study, the major allele was overtransmitted in cases versus
controls. Although it is unclear whether this same effect
may hold for other autism-related risk loci, the observation
is interesting and is one that merits further consideration in
the field.
Conclusions
In conclusion, the results of this study suggest that the joint
analysis of common-risk variants will be more effective in
Table 5: Results for the three genetic score groups.
Risk group (genetic 
score)
AGRE sample Seattle sample
Case/pseudo- control 
frequencies
OR (95% CI) Case/control 
frequencies
OR (95% CI)
Low (≤ 4)* 0.19/0.27 1.00 0.19/0.26 1.00
Intermediate (5 or 6) 0.61/0.63 1.61 (1.23 to 2.12) 0.64/0.66 1.78 (1.12 to 2.83)
High (≥ 7) 0.20/0.11 2.59 (1.50 to 4.47) 0.17/0.08 3.15 (1.25 to 7.99)
*Reference group.Carayol et al. Molecular Autism 2010, 1:4
http://www.molecularautism.com/content/1/1/4
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identifying subgroups of individuals at risk than using sin-
gle polymorphisms for risk assessment. The developed
score could be improved by adding additional genes and
environmental factors in the future.
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